FINWIRES · TerminalLIVE
FINWIRES

調査速報:CFRAはOneok Inc.の株式について「ホールド」の見解を維持します。

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。当社の12ヶ月目標株価96ドル(7ドル引き上げ)は、相対評価とDCFモデル分析を組み合わせたものです。相対評価では、OKEの過去のフォワード平均に沿って、2027年のEBITDA予測に企業価値の10.5倍を適用し、89ドルという評価額を算出しました。一方、DCFモデルでは、中期フリーキャッシュフロー成長率3.5%、終末期成長率2.0%を用い、WACC5.4%で割り引くと、1株当たり103ドルという評価額となります。2026年のEPS予想は0.09ドル引き上げ5.78ドル、2027年のEPS予想は0.06ドル引き下げ6.08ドルとしました。 OKEは、第1四半期に米国メキシコ湾岸パーミアン盆地のNGL取扱量が31%増加したと指摘したが、これは少なくとも部分的には中東情勢の混乱と、代替供給源を求める海外バイヤーの存在によるものと考えられる。成長投資と配当金支出を合わせると、2026年には営業キャッシュフローの約83%が消費されると推定され、一定の安全性は確保されているものの、同業他社と比べてわずかに優れている程度にとどまる。株価利回りは4.6%。

Related Articles

Sectors

Update: Gold Falls as the Dollar and Yields Climb

(Updates prices.)Gold traded lower midafternoon Monday as the dollar and yields rose, forcing the precious metal below the tight range it has stuck within for the past month.Gold for June delivery was last seen down US$112.20 to US$4,533.20 per ounce, the lowest since March 27.The war on Iran has prompted some safe-haven demand for the metal, even as the higher oil prices that followed the start of the war on Iran is hiking inflation. This is raising concerns higher interest rates are on the way, which is bearish for the metal since it pays no interest."Gold remains supported by safe-haven demand as investors continue to watch the Middle East conflict, oil prices, and the yen. Any durable easing in the Strait of Hormuz would likely cool demand for defensive assets, but until shipping flows normalise, gold should remain sensitive to geopolitical headlines and shifts in real yields," Saxo Bank noted.The dollar rose, with the ICE dollar index last seen up 0.2.9 points to 98.45. Treasury yields were sharply higher, with the U.S. two-year note last seen paying 3.975%, up 8.3 basis points, while the yield on the 10-year note as up 7.0 points to 4.449%

$GCM6$GLD
Australia

Top Midday Gainers

Celcuity (CELC) reported late Friday positive topline results from a cohort of its phase 3 Viktoria-1 trial, with the study meeting its primary endpoint and showing a clinically meaningful improvement in progression-free survival.The study evaluated gedatolisib plus fulvestrant, with or without palbociclib, in patients with HR-positive, HER2-negative, PIK3CA-mutant advanced breast cancer who had progressed after a CDK4/6 inhibitor and an aromatase inhibitor.Shares jumped more than 16%, with intraday trading volume at over 2.5 million from a daily average of roughly 737,000.CNS Pharmaceuticals (CNSP) shares surged 268% amid heavy trading after the company said Monday it signed deals for a private placement financing likely to generate roughly $22.5 million.Intraday trading volume catapulted to over 78.4 million shares from a daily average of about 32,000.American Express Global Business Travel, which is operated by Global Business Travel Group (GBTG), said Monday it has entered into a definitive agreement to be acquired by Long Lake Management for $9.50 per share in an all-cash deal valued at about $6.3 billion.Shares soared 57%, with intraday trading volume of over 61.6 million from a daily average of about 1.6 million.Price: $146.00, Change: $+20.35, Percent Change: +16.20%

$CELC$CNSP$GBTG
Sectors

Sector Update: Health Care Stocks Softer in Afternoon Trading

Health care stocks declined Monday afternoon, with the NYSE Health Care Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing 0.3%.The iShares Biotechnology ETF (IBB) rose 1.3%.In corporate news, Amgen (AMGN) said Monday it will invest an additional $300 million in its biologics manufacturing facility in Puerto Rico. Amgen shares were down 2.1%.Vanda Pharmaceuticals (VNDA) shares jumped past 5% after it said Monday its motion sickness drug Nereus is now commercially available in the US.Eli Lilly (LLY) shares added 0.2% after Barclays lifted the company's price target to $1,400 from $1,350, while keeping its overweight rating.Moderna (MRNA) is showing continued advancement across its pipeline, with progress in cancer vaccines and infectious disease programs supporting a more balanced risk-reward profile, RBC Capital Markets said in a note. RBC maintained its sector perform rating on the stock and raised its price target to $38 from $35. Moderna shares rose 4.6%.

$AMGN$LLY$MRNA$VNDA